The Treatment of Advanced Colorectal Cancer

Publication
Article
Special ReportsGastrointestinal Cancers (Issue 1)
Volume 1
Issue 1

Roberto Bordonaro, MD, chair, medical oncology, Garibaldi Hospital, Catania, Italy, discusses the treatment of patients with advanced colorectal cancer.

Roberto Bordonaro, MD, chair, medical oncology, Garibaldi Hospital, Catania, Italy, discusses the treatment of patients with advanced colorectal cancer (CRC).

Read more about the treatment of CRC andthe need for fullRASmutational analyses > >

Articles in this issue
The Identification of Molecular Subtypes of Gastric Cancer
The Identification of Molecular Subtypes of Gastric Cancer
Ramucirumab Combo Increases Survival in Gastric Cancer
Ramucirumab Combo Increases Survival in Gastric Cancer
<em>RAS</em> Status Matters in mCRC: Confirmed by Second-Line Data
<em>RAS</em> Status Matters in mCRC: Confirmed by Second-Line Data
New Standard of Neoadjuvant Care for Rectal Cancer Established
New Standard of Neoadjuvant Care for Rectal Cancer Established
Reducing the Risk of Relapse in Patients With Pancreatic Cancer
Reducing the Risk of Relapse in Patients With Pancreatic Cancer
Vismodegib Demonstrates Activity in Advanced Pancreatic Cancer
Vismodegib Demonstrates Activity in Advanced Pancreatic Cancer
The Treatment of Advanced Colorectal Cancer
The Treatment of Advanced Colorectal Cancer
Studies Emphasize Need for Full <em>RAS</em> Mutational Analyses in the Management of mCRC
Studies Emphasize Need for Full <em>RAS</em> Mutational Analyses in the Management of mCRC
TTP, OS Benefit Seen Following Treatment With TGF-β Inhibitor in HCC
TTP, OS Benefit Seen Following Treatment With TGF-β Inhibitor in HCC

Newsletter

Stay up to date on practice-changing data in community practice.

Subscribe Now!
Recent Videos
Targeted Therapy Options Sometimes Underutilized in Metastatic CRC
Targeted Therapy Options Sometimes Underutilized in Metastatic CRC
SUNLIGHT Findings Emphasize Role of VEGF Inhibition in Refractory CRC
SUNLIGHT Findings Emphasize Role of VEGF Inhibition in Refractory CRC
Fakih Discusses Phase 2 Trial of Balstilimab Plus Botensilimab in MSS mCRC
Fakih Discusses Phase 2 Trial of Balstilimab Plus Botensilimab in MSS mCRC
Preliminary Data Show the Potential of Balstilimab Plus Botensilimab in MSS mCRC
Preliminary Data Show the Potential of Balstilimab Plus Botensilimab in MSS mCRC
Innovative PET Imaging With Cu 64 Anti-CEA in Advanced Rectal Cancer
Innovative PET Imaging With Cu 64 Anti-CEA in Advanced Rectal Cancer
Dostarlimab: Game Changer in Rectal Cancer Treatment?
Dostarlimab: Game Changer in Rectal Cancer Treatment?
Regorafenib Continues to Benefit Patients With Advanced CRC
Regorafenib Continues to Benefit Patients With Advanced CRC
Rohit Gosain, MD; Rahul Gosain, MD; and Pamela L. Kunz, MD, presenting slides
The Role of ctDNA in Colorectal Cancer
Rohit Gosain, MD; Rahul Gosain, MD; and Pamela L. Kunz, MD, presenting slides
CheckMate 8HW: Nivolumab Plus Ipilimumab in MSI-High/dMMR Metastatic Colorectal Cancer
Real-World Outcomes and Sequencing in Metastatic Colorectal Cancer
Real-World Outcomes and Sequencing in Metastatic Colorectal Cancer
Related Content
Model for MA Plan Reimbursement Needs Second Look

Model for MA Plan Reimbursement Needs Second Look

Leslie Busby, MD
April 10th 2025
Article

Addressing issues such as congestive heart failure is important to providing safe care to patients with cancer.

Read More

Behind the FDA Approval of Fruquintinib for Previously Treated mCRC

Behind the FDA Approval of Fruquintinib for Previously Treated mCRC

Jordyn Sava;Arvind Dasari, MD, MS
November 15th 2023
Podcast

In season 4, episode 18 of Targeted Talks, Arvind Dasari, MD, MS, dives into the recent approval of fruquintinib for patients with metastatic colorectal cancer.

Listen

FDA Approves Nivolumab/Ipilimumab Combo in MSI-H/dMMR mCRC

FDA Approves Nivolumab/Ipilimumab Combo in MSI-H/dMMR mCRC

Jordyn Sava
April 8th 2025
Article

Based on data from the phase 3 CheckMate-8HW trial, the combination of nivolumab and ipilimumab has been approved by the FDA in metastatic colorectal cancer.

Read More

Special Episode: Insight on Targeting Rare Genomic Alterations in Colorectal Cancers

Special Episode: Insight on Targeting Rare Genomic Alterations in Colorectal Cancers

Michael J. Overman, MD;Nichole Tucker
July 15th 2021
Podcast

In season 2, episode 6 of Targeted Talks, Dr. Michael J. Overman, joins Targeted Oncology for a special discussion around rare genomic alterations in colorectal cancer

Listen

HIF-2α Inhibitors Make Significant Inroads in Renal Cell Carcinoma

HIF-2α Inhibitors Make Significant Inroads in Renal Cell Carcinoma

Tony Berberabe, MPH
April 7th 2025
Article

Read More

Insights from ASCO GI and the Future of CAR T-Cell Therapy in Solid Tumors

Insights from ASCO GI and the Future of CAR T-Cell Therapy in Solid Tumors

Robert L. Ferris, MD, PhD
April 4th 2025
Article

The GI Cancers Symposium revealed new therapies for specific cancer subsets and progress in chimeric antigen receptor T-cell therapies for solid tumors.

Read More